Imke H. Bartelink

Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis

Imke H. Bartelink, Arief Lalmohamed, Elisabeth M L van Reij et al. · The Lancet Haematology · 2016 · 288 citations · Full text

Medicine, Hematology, Pediatrics +16

Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial

Jurjan Aman, Erik Duijvelaar, Liza Botros et al. · The Lancet Respiratory Medicine · 2021 · 124 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +15

Association between Busulfan Exposure and Outcome in Children Receiving Intravenous Busulfan before Hematologic Stem Cell Transplantation

Imke H. Bartelink, Svetlana V. Belitser, M. Suttorp et al. · Biology of Blood and Marrow Transplantation · 2009 · 122 citations · Full text

Medicine, Hematology, Pediatrics +17

Immune Reconstitution Kinetics as an Early Predictor for Mortality using Various Hematopoietic Stem Cell Sources in Children

Imke H. Bartelink, Svetlana V. Belitser, Catherijne A. J. Knibbe et al. · Biology of Blood and Marrow Transplantation · 2012 · 121 citations · Full text

Life Sciences, Hematology, Immunology +14

Fludarabine and Exposure-Targeted Busulfan Compares Favorably with Busulfan/Cyclophosphamide-Based Regimens in Pediatric Hematopoietic Cell Transplantation: Maintaining Efficacy with Less Toxicity

Imke H. Bartelink, Elisabeth M L van Reij, Corinne Gerhardt et al. · Biology of Blood and Marrow Transplantation · 2013 · 108 citations · Full text

Medicine, Hematology, Oncology +17